Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/hep.26273 http://scihub22266oqcxt.onion/10.1002/hep.26273 23348596!7165689!23348596     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hepatology 2013 ; 58 (1): 86-97 Nephropedia Template TP {{tp|p=23348596|t=2013. The antimalarial ferroquine is an inhibitor of hepatitis C virus |pdf=|usr=}}{{23348596}} gab.com Text The antimalarial ferroquine is an inhibitor of hepatitis C virus JO: Hepatology http://www.kidney.de/pget.php?&tw=1&pmid=23348596 #FOAvip Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti-HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)-free treatments. Here, we report that ferroquine (FQ), an antimalarial ferrocenic analog of chloroquine, is a novel inhibitor of HCV. FQ potently inhibited HCV infection of hepatoma cell lines by affecting an early step of the viral life cycle. The antiviral activity of FQ on HCV entry was confirmed with pseudoparticles expressing HCV envelope glycoproteins E1 and E2 from six different genotypes. In addition to its effect on HCV entry, FQ also inhibited HCV RNA replication, albeit at a higher concentration. We also showed that FQ has no effect on viral assembly and virion secretion. Using a binding assay at 4 degrees C, we showed that FQ does not prevent attachment of the virus to the cell surface. Furthermore, virus internalization was not affected by FQ, whereas the fusion process was impaired in the presence of FQ as shown in a cell-cell fusion assay. Finally, virus with resistance to FQ was selected by sequential passage in the presence of the drug, and resistance was shown to be conferred by a single mutation in E1 glycoprotein (S327A). By inhibiting cell-free virus transmission using a neutralizing antibody, we also showed that FQ inhibits HCV cell-to-cell spread between neighboring cells. Combinations of FQ with IFN, or an inhibitor of HCV NS3/4A protease, also resulted in additive to synergistic activity. CONCLUSION: FQ is a novel, interesting anti-HCV molecule that could be used in combination with other direct-acting antivirals. Twit Text FOAVip The antimalarial ferroquine is an inhibitor of hepatitis C virus ????Hepatology http://www.kidney.de/pget.php?&tw=1&pmid=23348596 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23348596 #FOAvip English Wikipedia <ref>{{Cite pmid|23348596}}</ref> The antimalarial ferroquine is an inhibitor of hepatitis C virus #MMPMID23348596 Vausselin T; Calland N; Belouzard S; Descamps V; Douam F; Helle F; Francois C; Lavillette D; Duverlie G; Wahid A; Feneant L; Cocquerel L; Guerardel Y; Wychowski C; Biot C; Dubuisson J Hepatology 2013[Jul]; 58 (1): 86-97 PMID23348596show ga Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti-HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)-free treatments. Here, we report that ferroquine (FQ), an antimalarial ferrocenic analog of chloroquine, is a novel inhibitor of HCV. FQ potently inhibited HCV infection of hepatoma cell lines by affecting an early step of the viral life cycle. The antiviral activity of FQ on HCV entry was confirmed with pseudoparticles expressing HCV envelope glycoproteins E1 and E2 from six different genotypes. In addition to its effect on HCV entry, FQ also inhibited HCV RNA replication, albeit at a higher concentration. We also showed that FQ has no effect on viral assembly and virion secretion. Using a binding assay at 4 degrees C, we showed that FQ does not prevent attachment of the virus to the cell surface. Furthermore, virus internalization was not affected by FQ, whereas the fusion process was impaired in the presence of FQ as shown in a cell-cell fusion assay. Finally, virus with resistance to FQ was selected by sequential passage in the presence of the drug, and resistance was shown to be conferred by a single mutation in E1 glycoprotein (S327A). By inhibiting cell-free virus transmission using a neutralizing antibody, we also showed that FQ inhibits HCV cell-to-cell spread between neighboring cells. Combinations of FQ with IFN, or an inhibitor of HCV NS3/4A protease, also resulted in additive to synergistic activity. CONCLUSION: FQ is a novel, interesting anti-HCV molecule that could be used in combination with other direct-acting antivirals. |Aminoquinolines/*pharmacology[MESH] |Antiviral Agents/*therapeutic use[MESH] |Cell Line, Tumor[MESH] |Drug Synergism[MESH] |Ferrous Compounds/*pharmacology[MESH] |Hepacivirus/*drug effects/genetics[MESH] |Hepatitis C/prevention & control[MESH] |Humans[MESH] |Interferon-alpha/administration & dosage[MESH] |Metallocenes[MESH] |Proline/administration & dosage/analogs & derivatives[MESH] |Viral Envelope Proteins/drug effects/genetics[MESH] |Viral Nonstructural Proteins/antagonists & inhibitors[MESH] |Virus Internalization/*drug effects[MESH]The antimalarial ferroquine is an inhibitor of hepatitis C virus (epmc).pdf DeepDyve Pubget Overpricing